COMPARE · Data as of August 14, 2026
ETON vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. ETON scored 72.0, NBIX scored 88.1 — NBIX leads.
Compare another set
ETON
Eton Pharmaceuticals, Inc.
72
$58.86 · $1.7B
fundamentals as of
Score gap
16.1
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
88.1
$152.72 · $15.5B
fundamentals as of
The model, pillar by pillar (0–100 each)
ETON
stronger →← stronger
NBIX
76
Qualityreturns · margins · balance sheet
81
100
Growthrevenue & earnings expansion
96
50
Valuevaluation vs sector peers
88
NBIX is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ETON
NBIX
$15mC-
FCF
$870mC+
+81.5%A
Rev
+34.4%A
1.02C
D/E
0.12B+
150.9xD
P/E
22.3xB+
1.40B
PEG
0.49A
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ETON
NBIX
335% above
Price vs fair valuelower is cheaper
15% below
~54%/yr
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
-83%
1-yr DCF upside
-4%
-77%
5-yr DCF upside
+18%
-65%
10-yr DCF upside
+61%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ETON
Why this score
- Short track record
NBIX
Why this score
- Durable high returns
- Diluting shareholders
The companies
ETONEton Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Trading near 52-week high of $59.69 — momentum setup, limited technical margin of safety. Revenue growing +81% — in hypergrowth territory. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.33 (implying +6% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 116% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 150.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. P/S 15.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $15.5b. 18% off the 52-week high of $186.12. Revenue growing +34% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $213.13 (implying +40% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ETON and NBIX diverge
On the headline score the gap is 16.1 points in favor of NBIX. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueETON 50.0 · NBIX 88.2NBIX +38.2
- QualityETON 75.6 · NBIX 80.7NBIX +5.1
- GrowthETON 100.0 · NBIX 95.9ETON +4.1
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.